Annals of Oncology Advance Access published online on September 7, 2005
Annals of Oncology, doi:10.1093/annonc/mdi326
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; European Institute of Oncology, Milan, Italy
* To whom correspondence should be addressed. The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.
Review
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
2 Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
3 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
4 The Cancer Council Australia and University of Sydney, Sydney, NSW, Australia
5 Division of Gynecologic Oncology, Kantonsspital, St Gallen, Switzerland
6 Zentrum für Tumordiagnostik und Prävention, Silberturm, Grossacker, St Gallen, Switzerland
A. Goldhirsch, E-mail: aron.goldhirsch{at}ibcsg.org
Abstract Panel Members are listed in the Appendix.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Roepman, H. M. Horlings, O. Krijgsman, M. Kok, J. M. Bueno-de-Mesquita, R. Bender, S. C. Linn, A. M. Glas, and M. J. van de Vijver Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer Clin. Cancer Res., November 15, 2009; 15(22): 7003 - 7011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Guerrieri-Gonzaga, E. Botteri, M. Lazzeroni, N. Rotmensz, A. Goldhirsch, C. Varricchio, D. Serrano, M. Cazzaniga, F. Bassi, A. Luini, et al. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study Ann. Onc., October 25, 2009; (2009) mdp408v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hancke, M. D. Denkinger, J. Konig, C. Kurzeder, A. Wockel, D. Herr, M. Blettner, and R Kreienberg Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study Ann. Onc., October 13, 2009; (2009) mdp364v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hietanen Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer? Ann. Onc., October 1, 2009; 20(10): 1749 - 1751. [Full Text] [PDF]
|
|
|
|
 |
|
 A H Sims Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us? J. Clin. Pathol., October 1, 2009; 62(10): 879 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, and W. K. Kim Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis Ann. Onc., August 1, 2009; 20(8): 1337 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Ann. Onc., August 1, 2009; 20(8): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bueno-de-Mesquita, D. S. A. Nuyten, J. Wesseling, H. van Tinteren, S. C. Linn, and M. J. van de Vijver The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment Ann. Onc., July 21, 2009; (2009) mdp273v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Thomssen, N. Harbeck, J. Dittmer, S. R. Abraha-Spaeth, N. Papendick, A. Paradiso, B. Lisboa, F. Jaenicke, M. Schmitt, and M. Vetter Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens J Natl Cancer Inst, July 15, 2009; 101(14): 1028 - 1029. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target Endocr. Rev., June 1, 2009; 30(4): 343 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Falandry, P. A. Canney, G. Freyer, and L. Y. Dirix Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer Ann. Onc., April 1, 2009; 20(4): 615 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schootman, D. B. Jeffe, M. Lian, W. E. Gillanders, and R. Aft The Role of Poverty Rate and Racial Distribution in the Geographic Clustering of Breast Cancer Survival Among Older Women: A Geographic and Multilevel Analysis Am. J. Epidemiol., March 1, 2009; 169(5): 554 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hassett, M. E. Hughes, J. C. Niland, S. B. Edge, R. L. Theriault, Y.-N. Wong, J. Wilson, W. B. Carter, D. W. Blayney, and J. C. Weeks Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5553 - 5560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Weichselbaum, H. Ishwaran, T. Yoon, D. S. A. Nuyten, S. W. Baker, N. Khodarev, A. W. Su, A. Y. Shaikh, P. Roach, B. Kreike, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer PNAS, November 25, 2008; 105(47): 18490 - 18495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kyoda, S. Kinoshita, H. Takeyama, K. Uchida, and T. Morikawa HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions Oncologist, November 1, 2008; 13(11): 1137 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo, E. Steiner, A. Lebrecht, W. Siggelkow, W. Weikel, I. Schiffer-Petry, et al. Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5849 - 5855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Brewster, G. N. Hortobagyi, K. R. Broglio, S.-W. Kau, C. A. Santa-Maria, B. Arun, A. U. Buzdar, D. J. Booser, V. Valero, M. Bondy, et al. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy J Natl Cancer Inst, August 20, 2008; 100(16): 1179 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Regan, O. Pagani, B. Walley, R. Torrisi, E. A. Perez, P. Francis, G. F. Fleming, K. N. Price, B. Thurlimann, R. Maibach, et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann. Onc., July 1, 2008; 19(7): 1231 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Pignol, I. Olivotto, E. Rakovitch, S. Gardner, K. Sixel, W. Beckham, T. T. T. Vu, P. Truong, I. Ackerman, and L. Paszat A Multicenter Randomized Trial of Breast Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis J. Clin. Oncol., May 1, 2008; 26(13): 2085 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nole, E. Munzone, L. Zorzino, I. Minchella, M. Salvatici, E. Botteri, M. Medici, E. Verri, L. Adamoli, N. Rotmensz, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications Ann. Onc., May 1, 2008; 19(5): 891 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2601 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Viale, M. M. Regan, E. Maiorano, M. G. Mastropasqua, R. Golouh, T. Perin, R. W. Brown, A. Kovacs, K. Pillay, C. Ohlschlegel, et al. Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors--International Breast Cancer Study Group J. Clin. Oncol., March 20, 2008; 26(9): 1404 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chanrion, V. Negre, H. Fontaine, N. Salvetat, F. Bibeau, G. M. Grogan, L. Mauriac, D. Katsaros, F. Molina, C. Theillet, et al. A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1744 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marchionni, R. F. Wilson, A. C. Wolff, S. Marinopoulos, G. Parmigiani, E. B. Bass, and S. N. Goodman Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer Ann Intern Med, March 4, 2008; 148(5): 358 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Hadji Menopausal symptoms and adjuvant therapy-associated adverse events Endocr. Relat. Cancer, March 1, 2008; 15(1): 73 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Parton and I. E. Smith Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 745 - 752. [Full Text] [PDF]
|
|
|
|
|
|
G. Viale, M. M. Regan, M. G. Mastropasqua, F. Maffini, E. Maiorano, M. Colleoni, K. N. Price, R. Golouh, T. Perin, R. W. Brown, et al. Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer J Natl Cancer Inst, February 6, 2008; 100(3): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-P. P. Tran and J. L. Grabinski Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56. [Abstract] [PDF]
|
|
|
|
 |
|
 S. O. Wurtz, S. Moller, H. Mouridsen, P. B. Hertel, E. Friis, and N. Brunner Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer: A Prospective Study Mol. Cell. Proteomics, February 1, 2008; 7(2): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Laurentiis, G. Cancello, D. D'Agostino, M. Giuliano, A. Giordano, E. Montagna, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, et al. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials J. Clin. Oncol., January 1, 2008; 26(1): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kim, S. Nakayama, Y. Miyoshi, T. Taguchi, Y. Tamaki, T. Matsushima, Y. Torikoshi, S. Tanaka, T. Yoshida, H. Ishihara, et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer Ann. Onc., January 1, 2008; 19(1): 68 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Heaphy, K. B. Baumgartner, M. Bisoffi, R. N. Baumgartner, and J. K. Griffith Telomere DNA Content Predicts Breast Cancer Free Survival Interval Clin. Cancer Res., December 1, 2007; 13(23): 7037 - 7043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Guler, D. Iliopoulos, N. Guler, C. Himmetoglu, M. Hayran, and K. Huebner Wwox and Ap2{gamma} Expression Levels Predict Tamoxifen Response Clin. Cancer Res., October 15, 2007; 13(20): 6115 - 6121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Viale, M. M. Regan, E. Maiorano, M. G. Mastropasqua, P. Dell'Orto, B. B. Rasmussen, J. Raffoul, P. Neven, Z. Orosz, S. Braye, et al. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98 J. Clin. Oncol., September 1, 2007; 25(25): 3846 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury Oncologist, September 1, 2007; 12(9): 1055 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Klaeser, O Wiederkehr, D Koeberle, A Mueller, B Bubeck, and B Thuerlimann Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer Ann. Onc., August 1, 2007; 18(8): 1329 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pruthi, K. R. Brandt, A. C. Degnim, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, G. K. Dy, and J. N. Ingle A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis Mayo Clin. Proc., August 1, 2007; 82(8): 999 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dellapasqua, M. Colleoni, M. Castiglione, and A. Goldhirsch New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies Oncologist, August 1, 2007; 12(8): 952 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Chan A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer Ann. Onc., July 1, 2007; 18(7): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma and M. Clemons First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy Oncologist, July 1, 2007; 12(7): 785 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schmid, M. Untch, V. Kosse, G. Bondar, L. Vassiljev, V. Tarutinov, U. Lehmann, L. Maubach, J. Meurer, D. Wallwiener, et al. Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study J. Clin. Oncol., June 20, 2007; 25(18): 2509 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Ahn, B. H. Son, S. W. Kim, S. I. Kim, J. Jeong, S.-S. Ko, and W. Han Poor Outcome of Hormone Receptor-Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea--A Report From the Korean Breast Cancer Society J. Clin. Oncol., June 10, 2007; 25(17): 2360 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, A. Inoue, Y. Miki, T. Moriya, J.-i. Akahira, T. Ishida, H. Hirakawa, Y. Yamaguchi, S.-i. Hayashi, and H. Sasano Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor Endocr. Relat. Cancer, June 1, 2007; 14(2): 279 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yildirim-Assaf, A. Coumbos, W. Hopfenmuller, H.-D. Foss, H. Stein, and W. Kuhn The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer J. Clin. Pathol., June 1, 2007; 60(6): 649 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Karlsson, B. F. Cole, K. N. Price, A. S. Coates, M. Castiglione-Gertsch, B. A. Gusterson, E. Murray, J. Lindtner, J. P. Collins, S. B. Holmberg, et al. The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2019 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Di Leo The state of HER-2 status Ann. Onc., May 1, 2007; 18(5): 813 - 815. [Full Text] [PDF]
|
|
|
|
|
|
L Mauriac, A Keshaviah, M Debled, H Mouridsen, J. Forbes, B Thurlimann, R Paridaens, A Monnier, I Lang, A Wardley, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann. Onc., May 1, 2007; 18(5): 859 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al. CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients Clin. Cancer Res., May 1, 2007; 13(9): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Otsuki, S.-i. Shimizu, K. Suwa, M. Yoshida, M. Kanzaki, and H. Kobayashi Which is the Better Pathological Prognostic Factor, the Nottingham Histological Grade or the Japanese Nuclear Grade? A Large Scale Study with a Long-term Follow-up Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ma, Y. Qian, L. Wei, J. Abraham, X. Shi, V. Castranova, E. J. Harner, D. C. Flynn, and L. Guo Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling Clin. Cancer Res., April 1, 2007; 13(7): 2014 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Coates, A. Keshaviah, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. D. Gelber, M. Colleoni, et al. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 J. Clin. Oncol., February 10, 2007; 25(5): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Liu, X. Wang, G. Y. Chen, P. Dalerba, A. Gurney, T. Hoey, G. Sherlock, J. Lewicki, K. Shedden, and M. F. Clarke The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells N. Engl. J. Med., January 18, 2007; 356(3): 217 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Climent, P. Dimitrow, J. Fridlyand, J. Palacios, R. Siebert, D. G. Albertson, J. W. Gray, D. Pinkel, A. Lluch, and J. A. Martinez-Climent Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer Cancer Res., January 15, 2007; 67(2): 818 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kennecke, I. Olivotto, C Speers, B Norris, S. Chia, C Bryce, and K. Gelmon Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen Ann. Onc., January 1, 2007; 18(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Perey, R Paridaens, H Hawle, K Zaman, F Nole, H Wildiers, M Fiche, D Dietrich, P Clement, D Koberle, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann. Onc., January 1, 2007; 18(1): 64 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study Ann. Onc., January 1, 2007; 18(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Walshe, N. Denduluri, and S. M. Swain Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer J. Clin. Oncol., December 20, 2006; 24(36): 5769 - 5779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Goldhirsch, A. Coates, R. Gelber, J. Glick, B Thurlimann, H-J Senn, and On behalf of the St Gallen Expert Panel Members First--select the target: better choice of adjuvant treatments for breast cancer patients Ann. Onc., December 1, 2006; 17(12): 1772 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Regan, G. Viale, M. G. Mastropasqua, E. Maiorano, R. Golouh, A. Carbone, B. Brown, M. Suurkula, G. Langman, L. Mazzucchelli, et al. Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. J Natl Cancer Inst, November 1, 2006; 98(21): 1571 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ponzone, F Montemurro, F Maggiorotto, C Robba, D Gregori, M. Jacomuzzi, F Kubatzki, D Marenco, A Dominguez, N Biglia, et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer Ann. Onc., November 1, 2006; 17(11): 1631 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez Appraising Adjuvant Aromatase Inhibitor Therapy Oncologist, November 1, 2006; 11(10): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Ma, S. G. Hilsenbeck, W. Wang, L. Ding, D. C. Sgroi, R. A. Bender, C. K. Osborne, D. C. Allred, and M. G. Erlander The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer J. Clin. Oncol., October 1, 2006; 24(28): 4611 - 4619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Colleoni, N Rotmensz, G Peruzzotti, P Maisonneuve, L Orlando, R Ghisini, G Viale, G Pruneri, P Veronesi, A Luini, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease Ann. Onc., October 1, 2006; 17(10): 1497 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Urban, V. Vuaroqueaux, M. Labuhn, M. Delorenzi, P. Wirapati, E. Wight, H.-J. Senn, C. Benz, U. Eppenberger, and S. Eppenberger-Castori Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4245 - 4253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzaniga, G Mustacchi, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group Adjuvant systemic treatment of early breast cancer: the NORA study Ann. Onc., September 1, 2006; 17(9): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vocaturo, F. Novelli, M. Benevolo, G. Piperno, F. Marandino, A. M. Cianciulli, R. Merola, R. P. Donnorso, I. Sperduti, S. Buglioni, et al. Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep(R)-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era Oncologist, September 1, 2006; 11(8): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Ryan and P. E. Goss Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Oncologist, July 1, 2006; 11(7): 718 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy Ann. Onc., May 1, 2006; 17(5): 878 - 879. [Full Text] [PDF]
|
|
|
|
|
|
International Breast Cancer Study Group Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93 J. Clin. Oncol., March 20, 2006; 24(9): 1332 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Linke, T. M. Bremer, C. D. Herold, G. Sauter, and C. Diamond A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients Clin. Cancer Res., February 15, 2006; 12(4): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gerber, A. Krause, T. Reimer, I. Mylonas, J. Makovitzky, G. Kundt, and W. Janni Anastrozole versus Tamoxifen Treatment in Postmenopausal Women with Endocrine-Responsive Breast Cancer and Tamoxifen-Induced Endometrial Pathology Clin. Cancer Res., February 15, 2006; 12(4): 1245 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist, February 1, 2006; 11(2): 111 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Smith and S. Chua Medical treatment of early breast cancer. III: chemotherapy BMJ, January 21, 2006; 332(7534): 161 - 162. [Full Text] [PDF]
|
|